Craig Alfred Mckelvey

8030359, Oct 4, 2011

Feb 9, 2007

12/223272

Sarah Geers - Weehawken NJ, US
Michael Lowinger - Norristown PA, US
Craig A. McKelvey - Ambler PA, US
Robert F. Meyer - Royersford PA, US
Dina Zhang - Watchung NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

A01N 33/18
A01N 29/10
A61K 31/12

514676, 514754, 514684

A pharmaceutical composition comprises (a) a CETP inhibiting compound, or a pharmaceutically acceptable salt thereof; (b) a concentration-enhancing polymer, and (c) optionally one or more surfactants; wherein the compound has the structure shown as Formula I below. The composition raises HDL-cholesterol and lowers LDL-cholesterol.

8486983, Jul 16, 2013

Dec 5, 2006

12/085745

Agam R. Sheth - Lansdale PA, US
Bhagwant Rege - Collegeville PA, US
Soumojeet Ghosh - Lansdale PA, US
Laman L. Alani - Lansdale PA, US
Maria T. Cruanes - Lansdale PA, US
Craig A. McKelvey - Ambler PA, US

Merck Sharp & Dohme Corp. - Rahway NJ

A61K 31/421

514376

A liquid formulation for oral administration of the CETP inhibitor of formula (I) has improved bioavailability compared with conventional solid formulations. The formulation comprises the CETP inhibitor, or a pharmaceutically acceptable salt thereof; an oil; and one or more nonionic surfactants having a hydrophilic lipophilic balance (HLB)>10.

20070298099, Dec 27, 2007

Nov 18, 2005

11/667344

Andrey Peresypkin - Cranford NJ, US
Eleni Dokou - Harleysville PA, US
Craig McKelvey - Ambler PA, US
Charles DeLuca - Royersford PA, US
Laman Alani - Lansdale PA, US
Todd Gibson - North Haven CT, US
Danielle Euler - Souderton PA, US
Santipharp Panmai - West Point PA, US
W. Wuelfing - Schwenksville PA, US
Thomas Gandek - Collegeville PA, US
Drazen Ostovic - Newbury Park CA, US
Timothy Rhodes - South Orange NJ, US
Brian Hamilton - Lansdale PA, US

A61K 9/48
A61K 31/44
A61P 25/30
A61P 3/04
A61P 3/10

424456000, 514351000

N-[1S,2S]-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-trifluoromethyl]pyridine-2-yl}oxy}propanamide (Compound I) has surprisingly improved solubility and bioavailability in a lipophilic vehicle comprising a pharmaceutically acceptable digestible oil, a surfactant, or a cosolvent, or a mixture of any two or more thereof. In one embodiment of the present invention are self-emulsifying or self-microemulsifying composition comprising 1) Compound I; 2) a surfactant having an HLB of 1 to 8; and 3) a surfactant having an HLB of over 8 to 20; and optionally, 4) a digestible oil and/or cosolvent and/or antioxidant or preservative.

20090264436, Oct 22, 2009

Apr 17, 2009

12/386402

Craig McKelvey - Ambler PA, US
Sarah Geers - Newark NJ, US
Justin Moser - Collegeville PA, US
Bhagwant Rege - Collegeville PA, US
Dina Zhang - Watchung NJ, US
Sutthilug Sotthivirat - Lansdale PA, US

A61K 31/4985
A61K 31/44

514249, 514351

Described herein are solid, stable pharmaceutical formulations of cannabinoid receptor inverse agonists, such as taranabant, and processes of making such formulations. Additionally, described herein are solid stable pharmaceutical formulations of cannabiniod inverse agonists, such as taranabant, and an additional therapeutic agent, as well as processes for making such pharmaceutical formulations.

20090264476, Oct 22, 2009

Apr 17, 2009

12/386403

Craig McKelvey - Ambler PA, US
Sarah Geers - Newark NJ, US
Justin Moser - Collegeville PA, US
Bhagwant Rege - Collegeville PA, US
Dina Zhang - Watchung NJ, US
Sutthilug Sotthivirat - Lansdale PA, US

A61K 31/44
A61K 31/4985
A61P 3/04

514351, 514249

Described herein are solid, stable pharmaceutical formulations of cannabinoid receptor inverse agonists, such as taranabant, and processes of making such formulations. Additionally, described herein are solid stable pharmaceutical formulations of cannabinoid inverse agonists, such as taranabant, and an additional therapeutic agent, as well as processes for making such pharmaceutical formulations.

20100081642, Apr 1, 2010

Sep 14, 2009

12/558977

Eleni Dokou - Harleysville PA, US
Craig A. McKelvey - Ambler PA, US
Kevin R. McKenney - Lansdale PA, US
Andrey Peresypkin - Cambridge MA, US
Karen C. Thompson - Lansdale PA, US
W. Peter Wuelfing - Harleysville PA, US

A61K 31/4245
A61P 3/04
A61P 25/28

5142102

The present invention relates to pharmaceutical compositions that stabilize and improve the bioavailability of 3-[(1S)- 1-(1-{(S)-(4-chlorophenyl)[3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]methyl}azetidin-3-yl)-2-fluoro-2-methylpropyl]-5-fluorobenzonitrile. In particular, the present invention relates to pharmaceutical compositions that include 3-[(1S)-1-(1-{(S)-(4-chlorophenyl)[3 -(5-oxo-4,5-dihydro- 1,3,4-oxadiazol-2-yl)phenyl]methyl}azetidin-3-yl)-2-fluoro-2-methylpropyl]-5-fluorobenzonitrile and at least one pharmaceutical acceptable excipient, such as a mono-, di- or triglyceride.

20180228826, Aug 16, 2018

Jul 29, 2016

15/750056

- RAHWAY NJ, US
James DiNunzio - Bridgewater NJ, US
William A Marinaro - Scotch Plains NJ, US
Sutthilug Sotthivirat - Lansdale PA, US
Chad David Brown - Quakertown PA, US
Sundeep Sudish Dhareshwar - Whippany NJ, US
Jesse Lee Kuiper - North Wales PA, US
Yung-Chi Lee - New Providence NJ, US
Craig Alfred McKelvey - Ambler PA, US
Michael McNevin - Basking Ridge NJ, US
Elise Topol Miller - Gilbertsville PA, US
Li Xiong - Cedar Knolls NJ, US

MERCK SHARP & DOHME CORP. - RAHWAY NJ

A61K 31/7072
A61K 31/5365
A61K 31/4985
A61K 9/20
A61K 9/28

The present disclosure is directed to compositions comprising blended materials comprising a substantially crystalline HCV nucleotide polymerase inhibitor; a first solid dispersion formulation, which comprises an HCV NS5a inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof; and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and optionally one or more excipients; and a second solid dispersion formulation, which comprises an HCV NS3 inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof; and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and optionally one or more excipients. The present disclosure is also directed to oral dosage forms, such as tablets or capsules comprising the disclosed blended compositions comprising the disclosed solid dispersion formulations, and the methods for making these solid dispersion formulations and pharmaceutical compositions.

20180228827, Aug 16, 2018

Jul 29, 2016

15/750058

- RAHWAY NJ, US
David Harris - New Providence NJ, US
James DiNunzio - Bridgewater NJ, US
Sutthilug Sotthivirat - Lansdale PA, US
Sundeep Sudish Dhareshwar - Whippany NJ, US
Gerard Ross Klinzing - Wilmington DE, US
Jesse Lee Kuiper - North Wales PA, US
Yung-Chi Lee - New Providence NJ, US
Craig Alfred McKelvey - Ambler PA, US
Michael McNevin - Basking Ridge NJ, US
Li Xiong - Cedar Knolls NJ, US

MERCK SHARP & DOHME CORP. - RAHWAY NJ

A61K 31/7072
A61K 31/427
A61K 9/20
A61K 9/28
A61K 9/14

The present disclosure is directed to compositions comprising blended materials comprising a substantially crystalline HCV nucleotide polymerase inhibitor; a solid dispersion formulation, which comprises an HCV NS5a inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof, and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and optionally one or more excipients. The present disclosure is also directed to oral dosage forms, such as tablets or capsules comprising the disclosed blended compositions comprising the disclosed solid dispersion formulations, and the methods for making these solid dispersion formulations, and pharmaceutical compositions